{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:40:02Z","timestamp":1790196002121,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011597","name":"Valencia Department of Universal Healthcare and Public Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011597","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.urolonc.2025.10.015","type":"journal-article","created":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T23:40:54Z","timestamp":1763336454000},"page":"125.e1-125.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Urine metabolic analysis as a noninvasive method to diagnose prostate cancer"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5522-339X","authenticated-orcid":false,"given":"Jorge","family":"Panach-Navarrete","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vannina","family":"Gonz\u00e1lez-Marrachelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Morales-Tatay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Garc\u00eda-Morata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"Sales-Maicas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Monle\u00f3n-Salvado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0678-9287","authenticated-orcid":false,"given":"Jos\u00e9 Mar\u00eda","family":"Mart\u00ednez-Jabaloyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2025.10.015_bib0001","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"key":"10.1016\/j.urolonc.2025.10.015_bib0002","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.euros.2021.09.014","article-title":"Intervention-related deaths in the European randomized study of screening for prostate cancer","volume":"34","author":"Godtman","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.urolonc.2025.10.015_bib0003","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0094-0143(02)00188-X","article-title":"When to biopsy and when to stop biopsying","volume":"30","author":"Djavan","year":"2003","journal-title":"The Urol Clin North Am"},{"key":"10.1016\/j.urolonc.2025.10.015_bib0004","first-page":"116","article-title":"New markers in prostate cancer: Genomics","volume":"72","author":"Fuessel","year":"2019","journal-title":"Arch Esp Urol."},{"key":"10.1016\/j.urolonc.2025.10.015_bib0005","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1073\/pnas.0705685105","article-title":"Evidence of different metabolic phenotypes in humans","volume":"105","author":"Assfalg","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.urolonc.2025.10.015_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/metabo9030048","article-title":"Metabolomics contributions to the discovery of prostate cancer biomarkers","volume":"9","author":"G\u00f3mez-Cebri\u00e1n","year":"2019","journal-title":"Metabolites"},{"key":"10.1016\/j.urolonc.2025.10.015_bib0007","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.critrevonc.2017.08.002","article-title":"Urinary biomarkers in prostate cancer detection and monitoring progression","volume":"118","author":"Wu","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.urolonc.2025.10.015_bib0008","doi-asserted-by":"crossref","DOI":"10.1080\/20013078.2018.1470442","article-title":"Metabolic alterations in urine extracellular vesicles are associated to prostate cancer pathogenesis and progression","volume":"7","author":"Clos-Garcia","year":"2018","journal-title":"J Extracell Vesicles"},{"key":"10.1016\/j.urolonc.2025.10.015_bib0009","doi-asserted-by":"crossref","DOI":"10.1002\/nbm.3784","article-title":"Applications of high-resolution magic angle spinning MRS in biomedical studies II-human diseases","volume":"30","author":"Dietz","year":"2017","journal-title":"NMR Biomed"},{"key":"10.1016\/j.urolonc.2025.10.015_bib0010","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1158\/0008-5472.CAN-04-4106","article-title":"Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy","volume":"65","author":"Cheng","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2025.10.015_bib0011","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/pcan.2011.70","article-title":"Assessing prostate cancer growth with citrate measured by intact tissue proton magnetic resonance spectroscopy","volume":"15","author":"Dittrich","year":"2012","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urolonc.2025.10.015_bib0012","first-page":"2587","article-title":"High-throughput metabolomics enables biomarker discovery in prostate cancer","volume":"7","author":"Liang","year":"2017","journal-title":"CSR Adv"},{"key":"10.1016\/j.urolonc.2025.10.015_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/metabo7010009","article-title":"The role of sarcosine, uracil, and kynurenic acid metabolism in urine for diagnosis and progression monitoring of prostate cancer","volume":"7","author":"Gkotsos","year":"2017","journal-title":"Metabolites"},{"key":"10.1016\/j.urolonc.2025.10.015_bib0014","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jpba.2014.12.026","article-title":"Urine metabolic fingerprinting using LC-MS and GC-MS reveals metabolite changes in prostate cancer: a pilot study","volume":"111","author":"Struck-Lewicka","year":"2015","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.urolonc.2025.10.015_bib0015","doi-asserted-by":"crossref","DOI":"10.1038\/srep38243","article-title":"Prostate cancer patients-negative biopsy controls discrimination by untargeted metabolomics analysis of urine by LC-QTOF: upstream information on other omics","volume":"6","author":"Fern\u00e1ndez-Peralbo","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.urolonc.2025.10.015_bib0016","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.7150\/thno.19890","article-title":"Metabolomic profiling of extracellular vesicles and alternative normalization methods reveal enriched metabolites and strategies to study prostate cancer-related changes","volume":"7","author":"Puhka","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.urolonc.2025.10.015_bib0017","doi-asserted-by":"crossref","DOI":"10.1038\/srep42961","article-title":"Proteomic analysis of urinary extracellular vesicles from high Gleason score prostate cancer","volume":"7","author":"Fujita","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.urolonc.2025.10.015_bib0018","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11306-017-1194-y","article-title":"Non-invasive urinary metabolomic profiling discriminates prostate cancer from benign prostatic hyperplasia","volume":"13","author":"P\u00e9rez-Rambla","year":"2017","journal-title":"Metabolomics"},{"key":"10.1016\/j.urolonc.2025.10.015_bib0019","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/pros.23034","article-title":"Proteomics analysis of malignant and benign prostate tissue by 2D DIGE\/MS reveals new insights into proteins involved in prostate cancer","volume":"75","author":"Davalieva","year":"2015","journal-title":"Prostate"},{"key":"10.1016\/j.urolonc.2025.10.015_bib0020","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/978-3-319-67577-0_9","article-title":"Tryptophan catabolism and cancer immunotherapy targeting IDO mediated immune suppression","volume":"1036","author":"Amobi","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.urolonc.2025.10.015_bib0021","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.trsl.2015.07.003","article-title":"Therapeutic targeting of inflammation and tryptophan metabolism in colon and gastrointestinal cancer","volume":"167","author":"Santhanam","year":"2016","journal-title":"Transl Res"},{"key":"10.1016\/j.urolonc.2025.10.015_bib0022","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/nature07762","article-title":"Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression","volume":"457","author":"Sreekumar","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2025.10.015_bib0023","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1593\/neo.13314","article-title":"The role of sarcosine metabolism in prostate cancer progression","volume":"15","author":"Khan","year":"2013","journal-title":"Neoplasia"},{"key":"10.1016\/j.urolonc.2025.10.015_bib0024","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/pros.23198","article-title":"NMR spectroscopy of filtered serum of prostate cancer: a new frontier in metabolomics","volume":"76","author":"Kumar","year":"2016","journal-title":"Prostate"},{"key":"10.1016\/j.urolonc.2025.10.015_bib0025","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1021\/pr5011108","article-title":"Metabolomics-derived prostate cancer biomarkers: fact or fiction?","volume":"14","author":"Kumar","year":"2015","journal-title":"J Proteome Res"},{"key":"10.1016\/j.urolonc.2025.10.015_bib0026","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12894-015-0095-5","article-title":"A case control study of sarcosine as an early prostate cancer detection biomarker","volume":"15","author":"Ankerst","year":"2015","journal-title":"BMC Urol"},{"key":"10.1016\/j.urolonc.2025.10.015_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7150\/ijms.15783","article-title":"Amino acid profiles of serum and urine in search for prostate cancer biomarkers: a pilot study","volume":"14","author":"Derezi\u0144ski","year":"2017","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.urolonc.2025.10.015_bib0028","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nrc3557","article-title":"glycine and one-carbon units: cancer metabolism in full circle","volume":"13","author":"Serine","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.urolonc.2025.10.015_bib0029","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.eururo.2012.07.030","article-title":"Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay","volume":"63","author":"Hansen","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.10.015_bib0030","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1741-7015-6-19","article-title":"A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European randomized study of prostate cancer screening in Goteborg, Sweden","volume":"6","author":"Vickers","year":"2008","journal-title":"BMC Med"},{"key":"10.1016\/j.urolonc.2025.10.015_bib0031","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.tranon.2016.05.004","article-title":"Biomarker discovery in human prostate cancer: an update in metabolomics studies","volume":"9","author":"Lima","year":"2016","journal-title":"Trans Oncol"},{"key":"10.1016\/j.urolonc.2025.10.015_bib0032","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1002\/ijc.29576","article-title":"Metabolomic analysis of prostate cancer risk in a prospective cohort: the alpha-tocolpherol, beta-carotene cancer prevention (ATBC) study","volume":"137","author":"Mondul","year":"2015","journal-title":"Int J Cancer"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925004168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925004168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T12:30:45Z","timestamp":1769257845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925004168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1078143925004168"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.10.015","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urine metabolic analysis as a noninvasive method to diagnose prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}